T1	MajorClaim 0 86	Treatment-related quality of life (QOL) is an important aspect of diabetes management.
T3	Premise 858 990	Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.
T4	Premise 991 1189	The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.
T5	Premise 1190 1308	In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.
T6	Claim 1309 1421	Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.
R1	Support Arg1:T4 Arg2:T6	
R2	Support Arg1:T5 Arg2:T6	
